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Abstract
Recently, positron emission tomography (PET) imaging using PSMA-ligands has gained high attention as a promising
new radiotracer in patients with prostate cancer (PC). Several studies promise accurate staging of primary prostate
cancer and restaging after biochemical recurrence with 68Ga-PSMA ligand Positron emission tomography/computed
tomography (PET/CT). However, prospective trials and clinical guidelines for this new technique are still missing.
Therefore, we summarized our experience with 68Ga-PSMA ligand PET/CT examinations in patients with primary PC
and biochemical recurrence. It focuses on the technical and logistical aspects of 68Ga-PSMA ligand PET/CT examination
as well as on the specific background for image reading discussing also potential pitfalls. Further, it includes relevant
issues on free-text as well as structured reporting used in daily clinical routine.
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Background
Prostate cancer (PC) represents the most common
cancer in men and accounts for the third most cause for
cancer-associated death in men [1]. Early detection of
primary disease and its metastases is highly relevant in
terms of prognosis and therapy management. Primary
staging with conventional imaging modalities such as
computed tomography (CT) or magnetic resonance im-
aging (MRI) is limited as these techniques focus on mor-
phologic information and LN involvement is mainly
assessed by size. Up to 50 % of all patients undergoing
radical prostatectomy (RP) or radiotherapy (RT) for pri-
mary treatment of PC develop biochemical recurrence
[2–4]. Therefore, precise diagnosis of recurrence is cru-
cial for patient counselling and treatment selection.
However, the limited accuracy of CT or MRI in the
detection of local disease in patients with biochemical
recurrence is well appreciated [5, 6].
Positron emission tomography/computed tomography
(PET/CT) as a hybrid imaging technique combining
functional and morphological information has been
proven to exhibit high diagnostic accuracy and is in-
creasingly established as the primary staging tool in PC
and in patients with suspicious recurrent disease. Several
radiotracers have been proposed for molecular imaging
of PC including choline as a marker of membrane cell
proliferation. For recurrent PC, choline based (i.e. either
18F-Choline or 11C-Choline) PET/CT is currently widely
used in clinical routine, however, there have been numerous
studies reporting a low sensitivity and specificity [7, 8].
Especially in patients with prostate-specific antigen (PSA)-
values below 3 ng/ml the detection rate is reported to be
only 40–60 % [9–11].
Other radiotracers evaluated for PC include 11C-Acetate
and 18F-FACBC. 18F fluciclovine, a radiolabeled leucine
analog (1-amino-3-fluorocyclobutane-1-carboxylic acid in
the ‘anti’ configuration [18F FACBC]), is used to depict
amino acid transportation and has been found to be
successful in the assessment of primary and meta-
static PC showing also statistically significant superior
detection rates in comparison to 11C-Choline PET
[12–14]. 11C-Acetate is used as a PET radiotracer for
imaging PC via incorporation into intracellular phos-
phatidylcholine membrane microdomains in cancer
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Current clinical and scientific evidence for
68Ga-PSMA ligand PET/CT and potential indications
The prostate specific membrane antigene (PSMA) is a
transmembrane protein with significantly elevated ex-
pression in PC cells compared to benign prostatic tissue.
So far, several, mainly retrospective studies describe the
value of 68Ga-PSMA ligand PET/CT in different clinical
scenarios. All of them demonstrate a higher diagnostic
efficacy of 68Ga-PSMA ligand PET/CT compared to con-
ventional imaging including PET with other tracers (e.g.
18F-Choline, 11C-Choline) [7, 15–19]. In particular, 68Ga-
PSMA ligand PET/CT promises accurate staging of pri-
mary PC and re-staging after biochemical recurrence. In
a large study in primary intermediate to high-risk PC,
68Ga-PSMA-ligand imaging has been reported to clearly
improve detection of lymph node metastases compared
to morphological imaging thus potentially allowing for a
more tailored therapeutic concept [16].
Similar encouraging results were obtained for patients
with biochemical recurrence after radical prostatectomy
[17]. Here, 68Ga-PSMA ligand PET imaging has been
shown to increase detection of metastatic sites even at
low PSA-values in comparison to conventional imaging
or PET examination with different tracers [7]. More spe-
cifically, in a study of Afshar-Oromieh et al. 68Ga-PSMA
ligand PET/CT detected 78 lesions characteristic for re-
current PC in 32 patients while 18F-fluoromethylcholine
PET/CT detected only 56 lesions in 26 patients resulting
in a significant higher detection rate for 68Ga-PSMA lig-
and PET/CT [7]. The advantage of 68Ga-PSMA ligand
PET is especially evident in patients with low PSA levels
(PSA below 1 ng/ml). A recent study reported a detec-
tion rate of 73 and 58 % in patients with biochemical re-
currence after radical prostatectomy in a PSA-range of
0.5–1.0 ng/ml and 0.2–0.5 ng/ml, respectively [17]. This
facilitates the use of salvage procedures (e.g. secondary
lymphadenectomy, targeted radiation therapy) with a po-
tentially curative intent [20]. Although 68Ga-PSMA lig-
and PET seems to have an edge over morphological
imaging in patients with PC, the evaluation of PSMA-
negative PC comprising around 8 % of the examined pa-
tients remains a challenge [16].
In nuclear medicine, bone imaging with 99mTc-phos-
phonates plays an important role in the management of
PC patients according to current guidelines providing a
fast whole-body overview evaluating the presence of
bone metastases. Preliminary results from our depart-
ment indicate that the detection rate of 68Ga-PSMA lig-
and PET/CT is clearly superior to traditional bone scan
[21]. It has to be mentioned that in clinical practice
often faint uptake in various regions of the skeleton, es-
pecially in the ribs is found. Caution has to be taken in
these cases it remains unclear whether this uptake is
really related to bone metastasis or might also constitute
false positive findings. Nevertheless, in cases of moderate
or intense uptake (see below) usually no doubts exist
concerning the presence of bone metastases. Artigas et
al. recently reported about an increased 68Ga-PSMA lig-
and uptake in a patient with Paget’s disease probably re-
lated to an overexpression of PSMA in areas with an
abnormal bone remodelling and increased vascularity
[22]. In addition, healing fractures e.g. ribs or pelvis are
known to potentially show faint increased PSMA-ligand
uptake [23]. Nevertheless, currently data from multi-
centric prospective trials creating a high level of evi-
dence are still missing. Therefore and due to the novelty
of this technique the implementation in clinical guide-
lines is still missing. In addition, the reimbursement by
health-care providers is broadly varying as 68Ga-PSMA
ligand PET is still considered experimental. However, ac-
cording to the opinion of the authors of this article a
summary of the potential and reasonable indications for
PSMA-ligand PET/CT is provided in Table 1.
Furthermore, this review aims at helping physicians
and physicists to execute, interpret and document hybrid
68Ga-PSMA ligand PET/CT examinations. It focuses on
the technical and logistical issues as well as on the spe-
cific background for image reading with an emphasis on
the PET-part since contrast enhanced computed tomog-
raphy as the second part of a hybrid 68Ga-PSMA ligand
PET/CT examination is an already very standardized
and common imaging technique.
Synthesis, application and imaging protocol of
68Ga-PSMA ligand PET/CT
A number of different PSMA-targeted PET tracers have
been developed [24–27]. The most widely used PSMA-
ligand for PET-imaging in Europe is a 68Ga-labelled
PSMA inhibitor Glu-NH-CO-NH-Lys(Ahx)-HBED-CC
(68Ga PSMA HBED-CC) followed by the theranostic agent
68Ga-labelled PSMA I&T [26, 27]. Details on the synthesis
of 68Ga-labelled PSMA HBED-CC and 68Ga-labelled
PSMA I&T have been described previously [27, 28].
The 68Ga-PSMA ligand complex solution is applied
to patients via an intravenous bolus with an activity of
1.8–2.2 MBq per kilogram bodyweight. Variation of
injected radiotracer activity is caused by the short half-
life of 68Ga and variable elution efficiencies obtained
during the lifetime of the 68Ge/68Ga radionuclide gener-
ator. Low output of the 68Ge/68Ga radionuclide generator
could pose a major problem in institutions with high-
throughput as it can considerable lower the number of
patients that can be examined per 68Ga-PSMA ligand syn-
thesis. To optimize the number of patients it is recom-
mended to either inject patients in parallel in the case
several scanners are available at one site. In addition, in
our experience it seems feasible that patients with already
known diffuse metastatic disease (e.g. restaging after
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PSMA-radioligand therapy) are injected with only 2/3 of
the usual activity. In these advanced cases, the images ob-
tained still have reasonable quality allowing for adequate
judgement of therapy response.
Administration of diuretics (furosemide 20 mg) at time
of tracer injection is routinely used in our department to
enhance diuresis and improve image quality by reducing
artifacts due to high activity of 68Ga-PSMA ligand in the
bladder and the urinary collection system. Thus, it is
recommendable to ask the patient to empty the bladder
directly prior to the PET-scan. Besides no published data
on the image quality in examinations with and without
the application of furosemide we have seen considerable
“halo artefacts” around the parts of the urinary collec-
tion systems before starting to use diuresis. This seems
to be even more relevant when PET/MRI is used [29]. Add-
itionally, all patients receive diluted oral contrast (300 mg
Telebrix) and facultative a rectal filling with a negative con-
trast agent (100–150 mL). The latter allows better
anatomical delineation of the rectum and differentiating it
from adjacent structures, e.g. seminal vesicles or lymph
nodes. In our department (as in most other institutions)
PET acquisition is started approximately 60 min after tracer
injection. However, a study of Afshar-Oromieh et al. per-
forming 68Ga-PSMA ligand PET/CT 1 h and 3 h p.i con-
cluded that although suspicious PC lesions can be
evaluated with an excellent contrast as early as 1 h p.i. late
images (e.g. 3 h p.i.) may be help to further clarify unclear
lesions due to a better tumour to background ratio [30].
Nevertheless, it would be more complicated to fit this ap-
proach in schedule of a busy PET department, as most of
the other examination (mainly 18F-FDG) are also started
60 min p.i.
First a diagnostic CT scan is performed from base of the
skull-base to midthigh in the portal venous phase 80 s
after intravenous injection of contrast agent (1.5 ml per
kilogram bodyweight, e.g. Imeron 300, maximum 120 ml)
followed by the PET scan. Usually the PET-acquisition
starts from the midthigh to the head to exploit the re-
duced 68Ga-PSMA ligand uptake in the urinary bladder
directly after voiding. In addition, this minimizes misalign-
ment especially for the bladder which tends to be filled up
during the time of the examination. Technical and logis-
tical details for the applied diagnostic CT-examination
within a hybrid PET/CT-examination are described in
Boellaard et al. [31].
In our institution, all PET scans are acquired in 3D-
mode with an acquisition time of 3–4 min per bed pos-
ition. Emission data are corrected for randoms, dead time,
scatter, and attenuation and are reconstructed iteratively
by an ordered-subsets expectation maximization algo-
rithm (four iterations, eight subsets) followed by a postre-
construction smoothing Gaussian filter (5-mm full width
at one-half maximum) as applied by the different vendors.
Technical details on the reconstruction and post-
processing of PET-imaging data using 68Ga-labelled com-
pounds are described in Baum et al. [32].
Display of images
For image analysis all datasets are usually transferred to
a dedicated postprocessing workstation (e.g. Syngo
MMWP or Syngo Via, Siemens Medical Solutions,
Germany; Hermes Hybrid Viewer, Hermes Medical Solu-
tions, Sweden). The software packages for state-of-the-
art PET/CT analysis allow for parallel visualisation of
PET-, CT-, and PET + CT fusion images in the axial, cor-
onal, and sagittal planes as well as maximum intensity
projections in a 3D cine mode. In addition, they offer
the possibility of changing the SUV-threshold to e.g. as-
sess the uptake of PSMA-ligands in/or adjacent to or-
gans with high background (e.g. urinary bladder, kidney).
Morphological and functional imaging should be dis-
played at the same time and should be linked at the
Table 1 Potential indications for 68Ga-PSMA ligand PET/CT
Benefit using 68Ga-PSMA ligand PET/CT Patient group
High estimated benefit/diagnostic gain • Primary staging in high-risk
disease according to D’Amico
classification
• Biochemical recurrence with
low PSA-values (0.2 ng/ml to
10 ng/ml)a




Potential application with promising
preliminary data
• Biopsy targeting after previous
negative biopsy, but high




Potential application with current lack
of published data
•Monitoring of systemic








• Treatment monitoring in
metastatic castration-resistant
PC undergoing radioligand
therapy targeting PSMA (e.g.
177Lu-PSMA-ligand)
ain biochemical recurrence with PSA-values over 10 ng/ml conventional imaging
(e.g. CT, MRI, bone scan) is also able to demonstrate distribution of disease.
Furthermore, at PSA-values > 10 ng/ml salvage options facilitated by 68Ga-PSMA
ligand PET/CT are unlikely
bMonitoring of treatment in metastasized PC patients might be enhanced due
to often limited applicability of RECIST 1.1 criteria (e.g. non-target lymph node/
bone metastases without extra-osseous extension) and the ineffectiveness of
bone scan to reliably proving therapy response (e.g. flare phenomenon) compared to
preclinical data suggesting PSMA-expression as indicator for response assessment
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same table position. In addition, the diagnostic contrast-
enhanced CT scan should be evaluated according to the
established radiological criteria using a dedicated post-
processing workstation.
At our institution we routinely start reading the diag-
nostic CT scan, followed by a review of the accompanying
68Ga-PSMA ligand PET images with and without attenu-
ation correction. Both uncorrected and attenuation-
corrected images need to be assessed in order to identify
artifacts caused by contrast agents, metal implants and/or
patient motion. On all slices (of the attenuation corrected
data) quantitative information with respect to size and
68Ga-PSMA ligand uptake can be derived. Additionally
fused axial PET/CT images may be helpful for exact
localization of PET positive findings.
Pattern recognition tips/common variants and
artefacts
a) Interpretation Criteria for 68Ga-PSMA ligand PET/CT
A physiological variable PSMA-ligand uptake can
be observed in the following tissues: lacrimal
gland, parotid gland, submandibular gland, liver,
spleen, small intestine, colon and kidney as seen in
Fig. 1. Within healthy organs, kidneys and the
urinary collection system including the urinary
bladder as well as salivary glands are showing the
highest radiotracer uptake. However, especially in
localizations where PC metastases mostly occur-
the retroperitoneal fatty tissue, benign lymphatic
as well as bone tissue-hardly any uptake is noted
[33]. Care should be taken in heavily metastasized
patients as here visceral metastases can occur. Due
to high background activity in the liver potential
liver metastases can be obscured. In addition, in
advanced disease especially liver metastases tend
to loose PSMA-expression—most likely due to
de-differentiation. Therefore, in advanced disease
the diagnostic CT scan is the mainstay for
detection of liver metastases.
For 68Ga-PSMA ligand PET interpretation, first all
PET positive lesions suspicious for PC are noted.
In PET any focal uptake of 68Ga-PSMA ligand
higher than the surrounding background and not
associated with physiological uptake has to be
considered suspicious for malignancy and judged
and described below. As 68Ga-PSMA ligands are
excreted via the kidneys and are highly
accumulated in the urinary bladder, small local
recurrences might be missed. Therefore it is
especially important to evaluate PET images in axial
as well as coronal and sagittal planes and to change
the SUV-threshold to judge the PSMA-ligand uptake
in soft-tissue structures near the urinary bladder.
Examples of PC patients undergoing 68Ga-PSMA
ligand PET/CT examination for primary staging
and restaging are presented in Figs. 2 and 3.
Finally, it has to be noted that not all PC exhibit a
significant PSMA overexpression. In a study of
Maurer et al. about 8 % of patients with primary PC
did not show PSMA overexpression—with currently
Fig. 1 Maximum intensity protection (MIP) images of a patient with
physiological distribution of 68Ga-PSMA ligand. Accumulation is seen in
lacrimal and salivary glands, nasal mucosa, liver, spleen, bowel, kidneys
and bladder
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no specific biological explanation [16]. Therefore,
correct and careful interpretation of the diagnostic
CT scan as part of the 68Ga-PSMA ligand PET/CT
examination is of special importance.
b) Pitfalls of 68Ga-PSMA ligand PET
As 68Ga-PSMA ligand PET/CT imaging is a
relatively new imaging technique it is important to
be aware that 68Ga-PSMA ligands are not
completely specific for PC to avoid scan
misinterpretation. So far, several case reports exist
showing increased PSMA uptake in benign lesions
such as thyroid adenoma, Paget’s disease,
schwannoma, tuberculosis, adrenal adenoma or
splenic sarcoidosis [22, 34–36]. Further, it is
known that coeliac ganglia show a relevant
68Ga-PSMA uptake. In a study of Krohn et al. at
least one ganglion with tracer uptake was found in
76/85 patients (89.4 %) undergoing 68Ga-PSMA
ligand PET/CT examination which may mimic
lymph node metastases in this area [37]. An
example of a 68Ga-PSMA ligand PET/CT
examination with focal uptake in the coeliac
ganglion is presented in Fig. 4. Interestingly,
PSMA expression has also been reported in the
tumor neovasculature of some solid tumors
(e.g. colon, breast, renal) and in newly formed
blood vessels. Apart from PC, other malignant
lesions presenting with increased PSMA
expression have been reported for glioblastoma,
hepatocellular carcinoma, lung cancer, renal cell
carcinoma and thyroid cancer [38–42]. For
example, differentiation between lung metastases
and primary lung cancer which can also occur in
elderly patients as secondary malignancy is a
common clinical question. A study by Pyka et al.
revealed that quantitative (SUV) analysis of
68Ga-PSMA ligand PET was not able to
discriminate reliably between pulmonary
metastases and primary lung cancer in PC
patients as primary lung cancer lesions can also
Fig. 2 MIP a, c, e and fused 68Ga-PSMA ligand PET/CT b, d, f of a patient presenting with low 68Ga-PSMA ligand uptake in the left common iliac
artery (A and B, SUV mean 3.5), a patient presenting with moderate 68Ga-PSMA ligand uptake in the left internal iliac artery (SUV mean 7,8) and in
the left external iliac artery (C and D) and a patient presenting with intensive, focal 68Ga-PSMA ligand uptake behind the right common iliac vein
twice (E and F, SUV mean 17,9), Note the low uptake adjacent to the urinary bladder on the right side in the MIP images (E)
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show high PSMA-expression by 68Ga-PSMA
ligand PET. [41]. In summary, in unclear
68Ga-PSMA ligand PET positive lesions,
morphological correlation, further clarification
with other imaging techniques such as MRI,
ultrasound or biopsy is mandatory.
Formulating reports
At first, all important clinical data and technical details
of the 68Ga-PSMA ligand PET/CT examination should
be reported in a standardized way (Table 2). Reporting
of imaging findings is usually performed in a structured
way on a free text basis. We recommend the following
Fig. 4 68Ga-PSMA ligand PET/CT examination of a 76-year old patient after radical prostatectomy (Gleason score 8, pT2b, pN1) followed by subsequent
external beam radiation. 5 years later the patient presented with a rising PSA-value of 0.54 ng/ml. CT images show a 10 × 8 mm soft tissue formation in
the former left prostatic bed a and a morphologically unsuspicious 4 mm lymph node (short axis) d dorsal of the right external iliac vein. Corresponding
PET and fused PET/CT images show an intense, focal PSMA-ligand uptake in the former left prostatic bed b, c indicating a local recurrence as well as an
intense, focal PSMA-ligand uptake in the small-sized lymph node dorsal of the right external iliac vein e, f indicating a lymph node metastasis
Fig. 3 68Ga-PSMA ligand PET/CT in a 78-year old patient with primary PC (Gleason score 7, iPSA 34.3 ng/ml). The patient presented with intense,
multifocal uptake in the prostate b, d without correlate on CT images a The CT examination with bone window setting c and e shows osteoblastic
bone lesions in the left iliac bone as well as in the thoracic vertebrae with corresponding PSMA-ligand uptake in PET imaging f However, the focal
PSMA-ligand uptake in the right symphysis (B, D) shows only a slight hypersclerosis (C) on corresponding CT images that might have been missed
without PET. Note the physiological high uptake in the kidneys as well as moderate uptake in the liver and spleen (F)
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information and details to be included in the section
“findings” and “conclusion”.
Findings
Description of the localization, the extent and the inten-
sity of pathological 68Ga-PSMA ligand accumulations re-
lated to normal tissue. Hereby, a standardized reporting
should be pursued by reporting separately findings
within the prostatic fossa, lymph nodes, bones or other
visceral organs. 68Ga-PSMA ligand accumulation should
be reported as low, moderate or intense by comparison
to the background uptake in e.g. the liver parenchyma as
seen in Fig. 5. For each suspicious lesion, corresponding
SUVmax can be noted using a 3D isocontour VOI.
However, as so far no evidence exists that specific SUV-
thresholds aid in differentiation between benign and ma-
lignant lesions, at our institution quantitative SUVs are
not generally reported.
Relevant findings in CT and their relation to patho-
logical 68Ga-PSMA ligand accumulations should be
mentioned. However, the CT part of the 68Ga-PSMA lig-
and PET/CT report must describe all pathological find-
ings (even in the case they are PET negative).
Conclusion
The conclusion should address the findings with respect
to the clinical questions asked in the context of the
68Ga-PSMA ligand PET/CT examination. If possible, a
definite diagnosis with regard to local tumor involve-
ment, lymph node or bone metastases (and other if
present) should be stated. Alternatively, an estimate of
the probability of a diagnosis should be given. If relevant,
differential diagnoses should be discussed. If appropriate,
repeat examinations and/or additional examinations
should be recommended to clarify or confirm findings.
However, there is growing evidence that the classical
free-text reports of imaging studies have many possible
flaws, like inconsistency between different readers, differ-
ent nomenclature or incompleteness. Further, the narra-
tive individual form leads to reports that do not always
address key clinical questions, may contain clinically im-
portant errors and may contain ambiguous terms [43–45].
Besides, it is difficult to analyze information extracted
from free-text reports.
There are large initiatives for structured reporting for
different fields of imaging studies by several inter-
national societies [46]. Structured reporting assists in the
clear, complete, and consistent communication of results
by providing tools for physicians to adopt compliant
reporting guidelines (e.g. checklists, clinical decision
support). There are further efforts towards a unified
reporting nomenclature (e.g. the RadLex initiative in
Radiology) and towards information systems that sup-
port structured data storage and display report formats.
Table 2 Important clinical data and technical details of the
68Ga-PSMA ligand PET/CT examination
Clinical Notes:
In patients with primary PC the following information should be
included:
– date of diagnosis
– type of verification of diagnosis (biopsy results, time of biopsy,
Gleason score)
– current PSA value
– previous imaging results
– relevant further diagnoses (e.g. renal insufficiency, other
malignancies)
In patients with biochemical recurrence additional information is
necessary:
– previous surgery and therapy (e.g. antihormonal treatment,
radiation therapy, chemotherapy)
– initial PSA value, PSA nadir, facultative information on PSA-kinetics
Technical Details:
– exact name of the radiopharmaceutical agent and applied activity,
time of scan start post injection, number of bed positions and time
per bed position, body weight
– Information concerning medication administered as preparation of
the PET scan (e.g. furosemide)
– CT-protocol: low-dose or/and diagnostic CT, contrast agent application
(oral/rectal/ intravenous, information on concentrations and volumes,
native, arterial, portalvenous), scanned portion of the body
Fig. 5 Example of a 68Ga-PSMA ligand PET/CT examination with incidental finding of a moderate, focal PSMA-ligand uptake in a left-sided coeliac
ganglion in PET b and fused PET/CT images c. Corresponding CT images a show a teardrop-shaped soft tissue formation between the left adrenal
gland and the truncus coeliacus measuring about 9 × 3 mm, typical for a benign coeliac ganglion. Additionally, faint PSMA-ligand uptake in projection
on a smaller right-sided coeliac ganglion can be noted
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There have been publications for several tumor types
(pancreatic cancer and rectal cancer) which showed im-
proved satisfaction of referring physicians, higher com-
pleteness of reports when using specific report templates
or checklists [47–49]. This form of reporting involves
the presentation of a standard set of reporting items in a
standard sequence. In urogenital radiology structured
reporting is gaining more importance e.g. in the inter-
pretation of multiparametric MRI of the prostate using
the PIRADS classification [50, 51].
Based on these recent initiatives for structured report-
ing we developed a template for structured reporting of
68Ga-PSMA ligand PET/CT examination presented in
Fig. 6. The proposed structured report divides into three
categories: T-staging (primary tumor or local recurrence),
N-staging (abdominopelvic or cervical/thoracic lymph
nodes) and M-staging (bone). We used an online platform
that allows creation of decision trees for certain examina-
tions and concomitant report generation of semantic re-
ports by linking text elements to the decision trees
(https://www.smart-radiology.com).
Conclusions
PET imaging for PC using PSMA-ligands has gained high
attention during the last years. However, so far, no guide-
lines exist how to review and report 68Ga-PSMA ligand
PET/CT examinations in patients with PC. Therefore, in
this review we have summarized our approach performing
68Ga-PSMA ligand PET/CT scans and reviewing the im-
ages. We discussed important pitfalls in the evaluation of
Fig 6 Basic template for a decision tree for structured reporting of 68Ga-PSMA ligand PET/CT examinations. Please note that this decision tree
only contains the structured elements for local tumor involvement (primary tumor and local recurrence) as well as possible lymph node and
bone metastases as the most common findings in PC. Nevertheless all other potential malignant lesions/other pathological findings have to be
noted but exceed the scope of this figure
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68Ga-PSMA ligand PET/CT examinations and outlined im-
portant aspects for free-text as well as structured reports in
daily clinical routine. In addition, we have outlined potential
indications with an emphasis on the estimated clinical
benefit.
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